Lakeview Capital Partners LLC Decreases Position in GlaxoSmithKline PLC (NYSE:GSK)

Lakeview Capital Partners LLC lowered its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 12.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,647 shares of the pharmaceutical company’s stock after selling 1,090 shares during the period. Lakeview Capital Partners LLC’s holdings in GlaxoSmithKline PLC were worth $330,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Capstone Asset Management Co. raised its position in shares of GlaxoSmithKline PLC by 6.7% in the first quarter. Capstone Asset Management Co. now owns 102,668 shares of the pharmaceutical company’s stock valued at $4,328,000 after buying an additional 6,420 shares during the period. Jacobs & Co. CA raised its position in shares of GlaxoSmithKline PLC by 5.6% in the first quarter. Jacobs & Co. CA now owns 80,093 shares of the pharmaceutical company’s stock valued at $3,376,000 after buying an additional 4,270 shares during the period. Regentatlantic Capital LLC purchased a new position in shares of GlaxoSmithKline PLC during the first quarter valued at $268,000. Bank of Montreal Can raised its position in shares of GlaxoSmithKline PLC by 8.8% in the first quarter. Bank of Montreal Can now owns 128,238 shares of the pharmaceutical company’s stock valued at $5,407,000 after buying an additional 10,412 shares during the period. Finally, Highland Capital Management LLC raised its position in shares of GlaxoSmithKline PLC by 13.7% in the first quarter. Highland Capital Management LLC now owns 79,249 shares of the pharmaceutical company’s stock valued at $3,341,000 after buying an additional 9,520 shares during the period. 8.96% of the stock is owned by institutional investors and hedge funds.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 40.30 on Tuesday. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.93. The company has a market capitalization of $98.49 billion, a PE ratio of 39.74 and a beta of 1.03. The company has a 50 day moving average price of $42.68 and a 200 day moving average price of $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.87%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 194.00%.

COPYRIGHT VIOLATION WARNING: “Lakeview Capital Partners LLC Decreases Position in GlaxoSmithKline PLC (NYSE:GSK)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/08/08/lakeview-capital-partners-llc-decreases-position-in-glaxosmithkline-plc-nysegsk.html.

GSK has been the subject of a number of analyst reports. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Friday, June 16th. TheStreet raised GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. Finally, Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply